Lamotrigine Reduces β-Site AβPP-Cleaving Enzyme 1 Protein Levels Through Induction of Autophagy

Journal of Alzheimer's Disease

Volumn 46, Issue 4, 2015, Pages 863-876

  Wu, Hao ^a   Lu, Mei Hong ^a   Wang, Wang ^a   Zhang, Mao Ying ^b   Zhu, Qian Qian ^a   Xia, Yi Yuan ^a   Xu, Ru Xiang ^b   Yang, Yi ^b   Chen, Li Hua ^b   Ma, Quan Hong ^a  

^a SOOCHOW UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; autophagy; BACE1; CREB; lamotrigine; mTOR

Indexed keywords

3 METHYLADENINE; AMYLOID BETA PROTEIN; BETA SECRETASE 1; CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; LAMOTRIGINE; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; 3-METHYLADENINE; ADENINE; AMYLOID PRECURSOR PROTEIN; ASPARTIC PROTEINASE; BACE1 PROTEIN, HUMAN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; GREEN FLUORESCENT PROTEIN; PRESENILIN 1; SECRETASE; TRIAZINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AUTOPHAGY; CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HEK293 CELL LINE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; ALZHEIMER DISEASE; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CHO CELL LINE; CRICETULUS; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HIPPOCAMPUS; METABOLISM; MUTATION; PATHOLOGY;

ADENINE; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; AUTOPHAGY; CHO CELLS; CREB-BINDING PROTEIN; CRICETULUS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GREEN FLUORESCENT PROTEINS; HIPPOCAMPUS; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; PRESENILIN-1; TRIAZINES;

EID: 84937044564     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-143162     Document Type: Article

References (77)

1. Masters CL, Beyreuther K (2006) Alzheimer's centennial legacy: Prospects for rational therapeutic intervention targeting the Abeta amyloid pathway. Brain 129, 2823-2839.
2. Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, Wong PC (2001) BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci 4, 233-234.
3. Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, Martin L, Louis JC, Yan Q, Richards WG, Citron M, Vassar R (2001) Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci 4, 231-232.
4. Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, Freedman SB, Frigon NL, Games D, Hu K, Johnson-Wood K, Kappenman KE, Kawabe TT, Kola I, Kuehn R, Lee M, Liu WQ, Motter R, Nichols NF, Power M, Robertson DW, Schenk D, Schoor M, Shopp GM, Shuck ME, Sinha S, Svensson KA, Tatsuno G, Tintrup H, Wijsman J, Wright S, McConlogue L (2001) BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: Implications for Alzheimer's disease therapeutics. Hum Mol Genet 10, 1317-1324.
5. Ohno M, Sametsky EA, Younkin LH, Oakley H, Younkin SG, Citron M, Vassar R, Disterhoft JF (2004) BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron 41, 27-33.
6. Yang LB, Lindholm K, Yan R, Citron M, Xia W, Yang XL, Beach T, Sue L, Wong P, Price D, Li R, Shen Y (2003) Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med 9, 3-4.
7. Johnston JA, Liu WW, Todd SA, Coulson DT, Murphy S, Irvine GB, Passmore AP (2005) Expression and activity of beta-site amyloid precursor protein cleaving enzyme in Alzheimer's disease. Biochem Soc Trans 33, 1096-1100.
8. Holsinger RM, McLean CA, Beyreuther K, Masters CL, Evin G (2002) Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann Neurol 51, 783-786.
9. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P, Gudbjartsson D, Maloney J, Hoyte K, Gustafson A, Liu Y, Lu Y, Bhangale T, Graham RR, Huttenlocher J, Bjornsdottir G, Andreassen OA, Jonsson EG, Palotie A, Behrens TW, Magnusson OT, Kong A, Thorsteinsdottir U, Watts RJ, Stefansson K (2012) A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488, 96-99.
10. Vassar R (2014) BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res Ther 6, 89.
11. Hong L, Koelsch G, Lin X, Wu S, Terzyan S, Ghosh AK, Zhang XC, Tang J (2000) Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science 290, 150-153.
12. Guven M, Bozdemir H, Gunay I, Sarica Y, Kahraman I, Koc F (2006) The actions of lamotrigine and levetiracetam on the conduction properties of isolated rat sciatic nerve. Eur J Pharmacol 553, 129-134.
13. Kuo CC, Lu L (1997) Characterization of lamotrigine inhibition of Na+ channels in rat hippocampal neurones. Br J Pharmacol 121, 1231-1238.
14. Zona C, Avoli M (1997) Lamotrigine reduces voltage-gated sodium currents in rat central neurons in culture. Epilepsia 38, 522-525.
15. Stefani A, Spadoni F, Siniscalchi A, Bernardi G (1996) Lamotrigine inhibits Ca2+ currents in cortical neurons: Functional implications. Eur J Pharmacol 307, 113-116.
16. Zona C, Tancredi V, Longone P, D'Arcangelo G, D'Antuono M, Manfredi M, Avoli M (2002) Neocortical potassium currents are enhanced by the antiepileptic drug lamotrigine. Epilepsia 43, 685-690.
17. Poolos NP, Migliore M, Johnston D (2002) Pharmacological upregulation of h-channels reduces the excitability of pyramidal neuron dendrites. Nat Neurosci 5, 767-774.
18. Barbosa L, Berk M, Vorster M (2003) A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry 64, 403-407.
19. Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, Luckenbaugh DA, Cora-Ocatelli G, Leverich GS, Post RM (2000) A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 20, 607-614.
20. Malik S, Arif H, Hirsch LJ (2006) Lamotrigine and its applications in the treatment of epilepsy and other neurological and psychiatric disorders. Expert Rev Neurother 6, 1609-1627.
21. Zhang MY, Zheng CY, Zou MM, Zhu JW, Zhang Y, Wang J, Liu CF, Li QF, Xiao ZC, Li S, Ma QH, Xu RX (2014) Lamotrigine attenuates deficits in synaptic plasticity and accumulation of amyloid plaques in APP/PS1 transgenic mice. Neurobiol Aging 35, 2713-2725.
22. Cuervo AM (2004) Autophagy: In sickness and in health. Trends Cell Biol 14, 70-77.
23. Seok S, Fu T, Choi SE, Li Y, Zhu R, Kumar S, Sun X, Yoon G, Kang Y, Zhong W, Ma J, Kemper B, Kemper JK (2014) Transcriptional regulation of autophagy by an FXR-CREB axis. Nature 516, 108-111.
24. Jung CH, Ro SH, Cao J, Otto NM, Kim DH (2010) mTOR regulation of autophagy. FEBS Lett 584, 1287-1295.
25. Bao XQ, Li N, Wang T, Kong XC, Tai WJ, Sun H, Zhang D (2013) FLZ alleviates the memory deficits in transgenic mouse model of Alzheimer's disease via decreasing beta-amyloid production and tau hyperphosphorylation. PLoS One 8, e78033.
26. Liang B, Duan BY, Zhou XP, Gong JX, Luo ZG (2010) Calpain activation promotes BACE1 expression, amyloid precursor protein processing, and amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J Biol Chem 285, 27737-27744.
27. Abelaira HM, Reus GZ, Ribeiro KF, Zappellini G, Ferreira GK, Gomes LM, Carvalho-Silva M, Luciano TF, Marques SO, Streck EL, Souza CT, Quevedo J (2011) Effects of acute and chronic treatment elicited by lamotrigine on behavior, energy metabolism, neurotrophins and signaling cascades in rats. Neurochem Int 59, 1163-1174.
28. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14, 1296-1302.
29. Scott PH, Brunn GJ, Kohn AD, Roth RA, Lawrence JC Jr (1998) Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. Proc Natl Acad Sci U S A 95, 7772-7777.
30. Chalovich EM, Zhu JH, Caltagarone J, Bowser R, Chu CT (2006) Functional repression of cAMP response element in 6-hydroxydopamine-treated neuronal cells. J Biol Chem 281, 17870-17881.
31. Shaywitz AJ, Greenberg ME (1999) CREB: A stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem 68, 821-861.
32. Li XY, Zhan XR, Liu XM, Wang XC (2011) CREB is a regulatory target for the protein kinase Akt/PKB in the differentiation of pancreatic ductal cells into islet beta-cells mediated by hepatocyte growth factor. Biochem Biophys Res Commun 404, 711-716.
33. Peltier J, O'Neill A, Schaffer DV (2007) PI3K/Akt and CREB regulate adult neural hippocampal progenitor proliferation and differentiation. Dev Neurobiol 67, 1348-1361.
34. Maiese K, Chong ZZ, Wang S, Shang YC (2012) Oxidant stress and signal transduction in the nervous system with the PI 3-K, Akt, and mTOR cascade. Int J Mol Sci 13, 13830-13866.
35. Mizushima N, Yoshimori T, Levine B (2010) Methods in mammalian autophagy research. Cell 140, 313-326.
36. Tekin S, Aykut-Bingol C, Tanridag T, Aktan S (1998) Antiglutamatergic therapy in Alzheimer's disease-effects of lamotrigine. Short communication. J Neural Transm 105, 295-303.
37. Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, Devidze N, Ho K, Yu GQ, Palop JJ, Mucke L (2012) Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci U S A 109, E2895-E2903.
38. Zhang J, Zhang Y, Li J, Xing S, Li C, Li Y, Dang C, Fan Y, Yu J, Pei Z, Zeng J (2012) Autophagosomes accumulation is associated with beta-amyloid deposits and secondary damage in the thalamus after focal cortical infarction in hypertensive rats. J Neurochem 120, 564-573.
39. Yu WH, Kumar A, Peterhoff C, Shapiro Kulnane L, Uchiyama Y, Lamb BT, Cuervo AM, Nixon RA (2004) Autophagic vacuoles are enriched in amyloid precursor protein-secretase activities: Implications for beta-amyloid peptide over-production and localization in Alzheimer's disease. Int J Biochem Cell Biol 36, 2531-2540.
40. Koh YH, von Arnim CA, Hyman BT, Tanzi RE, Tesco G (2005) BACE is degraded via the lysosomal pathway. J Biol Chem 280, 32499-32504.
41. Wang R, Ying Z, Zhao J, Zhang Y, Wang R, Lu H, Deng Y, Song W, Qing H (2012) Lys(203) and Lys(382) are essential for the proteasomal degradation of BACE1. Curr Alzheimer Res 9, 606-615.
42. Zhang Y, Xiong M, Yan RQ, Sun FY (2010) Mutant ubiquitin-mediated beta-secretase stability via activation of caspase-3 is related to beta-amyloid accumulation in ischemic striatum in rats. J Cereb Blood Flow Metab 30, 566-575.
43. Kang EL, Cameron AN, Piazza F, Walker KR, Tesco G (2010) Ubiquitin regulates GGA3-mediated degradation of BACE1. J Biol Chem 285, 24108-24119.
44. Ding Y, Ko MH, Pehar M, Kotch F, Peters NR, Luo Y, Salamat SM, Puglielli L (2012) Biochemical inhibition of the acetyltransferases ATase1 and ATase2 reduces beta-secretase (BACE1) levels and Abeta generation. J Biol Chem 287, 8424-8433.
45. Pehar M, Puglielli L (2013) Lysine acetylation in the lumen of the ER: A novel and essential function under the control of the UPR. Biochim Biophys Acta 1833, 686-697.
46. Jonas MC, Costantini C, Puglielli L (2008) PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1. EMBO Rep 9, 916-922.
47. Costantini C, Ko MH, Jonas MC, Puglielli L (2007) A reversible form of lysine acetylation in the ER and Golgi lumen controls the molecular stabilization of BACE1. Biochem J 407, 383-395.
48. Charlwood J, Dingwall C, Matico R, Hussain I, Johanson K, Moore S, Powell DJ, Skehel JM, Ratcliffe S, Clarke B, Trill J, Sweitzer S, Camilleri P (2001) Characterization of the glycosylation profiles of Alzheimer's beta -secretase protein Asp-2 expressed in a variety of cell lines. J Biol Chem 276, 16739-16748.
49. von Arnim CA, Tangredi MM, Peltan ID, Lee BM, Irizarry MC, Kinoshita A, Hyman BT (2004) Demonstration of BACE (beta-secretase) phosphorylation and its interaction with GGA1 in cells by fluorescence-lifetime imaging microscopy. J Cell Sci 117, 5437-5445.
50. Walter J, Fluhrer R, Hartung B, Willem M, Kaether C, Capell A, Lammich S, Multhaup G, Haass C (2001) Phosphorylation regulates intracellular trafficking of beta-secretase. J Biol Chem 276, 14634-14641.
51. Dowling RJ, Topisirovic I, Fonseca BD, Sonenberg N (2010) Dissecting the role of mTOR: Lessons from mTOR inhibitors. Biochim Biophys Acta 1804, 433-439.
52. Jiang J, Jiang J, Zuo Y, Gu Z (2013) Rapamycin protects the mitochondria against oxidative stress and apoptosis in a rat model of Parkinson's disease. Int J Mol Med 31, 825-832.
53. Malagelada C, Jin ZH, Jackson-Lewis V, Przedborski S, Greene LA (2010) Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease. J Neurosci 30, 1166-1175.
54. Floto RA, Sarkar S, Perlstein EO, Kampmann B, Schreiber SL, Rubinsztein DC (2007) Small molecule enhancers of rapamycin-induced TOR inhibition promote autophagy, reduce toxicity in Huntington's disease models and enhance killing of mycobacteria by macrophages. Autophagy 3, 620-622.
55. Sarkar S, Krishna G, Imarisio S, Saiki S, O'Kane CJ, Rubinsztein DC (2008) A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. Hum Mol Genet 17, 170-178.
56. Bove J, Martinez-Vicente M, Vila M (2011) Fighting neurodegeneration with rapamycin: Mechanistic insights. Nat Rev Neurosci 12, 437-452.
57. Caccamo A, Majumder S, Richardson A, Strong R, Oddo S (2010) Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and tau: Effects on cognitive impairments. J Biol Chem 285, 13107-13120.
58. Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza O, Bredesen D, Richardson A, Strong R, Galvan V (2010) Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS One 5, e9979.
59. Liu YD, Su Y, Wang JJ, Sun SG, Wang T, Qiao X, Run XQ, Li H, Liang ZH (2013) Rapamycin decreases tau phosphorylation at Ser214 through regulation of cAMP-dependent kinase. Neurochem Int 62, 458-467.
60. Tang SJ, Reis G, Kang H, Gingras AC, Sonenberg N, Schuman EM (2002) A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. Proc Natl Acad Sci U S A 99, 467-472.
61. Cai Z, Yan LJ (2013) Rapamycin, autophagy, and Alzheimer's disease. J Biochem Pharmacol Res 1, 84-90.
62. Nixon RA, Yang DS (2011) Autophagy failure in Alzheimer's disease-locating the primary defect. Neurobiol Dis 43, 38-45.
63. Xiong ZG, Chu XP, MacDonald JF (2001) Effect of lamotrigine on the Ca(2+)-sensing cation current in cultured hippocampal neurons. J Neurophysiol 86, 2520-2526.
64. Wang JF, Sun X, Chen B, Young LT (2002) Lamotrigine increases gene expression of GABA-A receptor beta3 subunit in primary cultured rat hippocampus cells. Neuropsychopharmacology 26, 415-421.
65. Bechtold DA, Miller SJ, Dawson AC, Sun Y, Kapoor R, Berry D, Smith KJ (2006) Axonal protection achieved in a model of multiple sclerosis using lamotrigine. J Neurol 253, 1542-1551.
66. Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T, Wen H, Chiang HC, Xu G, Koliatsos VE, Borchelt DR, Price DL, Lee HK, Wong PC (2005) BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci 25, 11693-11709.
67. Cheng X, He P, Lee T, Yao H, Li R, Shen Y (2014) High activities of BACE1 in brains with mild cognitive impairment. Am J Pathol 184, 141-147.
68. Filser S, Ovsepian SV, Masana M, Blazquez-Llorca L, Brandt Elvang A, Volbracht C, Muller MB, Jung CK, Herms J (2014) Pharmacological inhibition of BACE1 impairs synaptic plasticity and cognitive functions. Biol Psychiatry 77, 729-739.
69. Savonenko AV, Melnikova T, Laird FM, Stewart KA, Price DL, Wong PC (2008) Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc Natl Acad Sci U S A 105, 5585-5590.
70. Hu X, He W, Diaconu C, Tang X, Kidd GJ, Macklin WB, Trapp BD, Yan R (2008) Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves. FASEB J 22, 2970-2980.
71. Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp BD, Yan R (2006) Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci 9, 1520-1525.
72. Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, DeStrooper B, Saftig P, Birchmeier C, Haass C (2006) Control of peripheral nerve myelination by the beta-secretase BACE1. Science 314, 664-666.
73. Rajapaksha TW, Eimer WA, Bozza TC, Vassar R (2011) The Alzheimer's beta-secretase enzyme BACE1 is required for accurate axon guidance of olfactory sensory neurons and normal glomerulus formation in the olfactory bulb. Mol Neurodegener 6, 88.
74. Hitt B, Riordan SM, Kukreja L, Eimer WA, Rajapaksha TW, Vassar R (2012) beta-Site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1)-deficient mice exhibit a close homolog of L1 (CHL1) loss-of-function phenotype involving axon guidance defects. J Biol Chem 287, 38408-38425.
75. Cao L, Rickenbacher GT, Rodriguez S, Moulia TW, Albers MW (2012) The precision of axon targeting of mouse olfactory sensory neurons requires the BACE1 protease. Sci Rep 2, 231.
76. Hu X, He W, Luo X, Tsubota KE, Yan R (2013) BACE1 regulates hippocampal astrogenesis via the Jagged1-Notch pathway. Cell Rep 4, 40-49.
77. Brodie MJ, Overstall PW, Giorgi L (1999) Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res 37, 81-87.